Stock Events

Stock Events

Cellectar Biosciences 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q1 2026
Next
-1.62
-1.23
-0.84
-0.46
Expected EPS
-0.4564612
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-19.03MNet Income

Analyst Ratings

7.59Average Price Target
The highest estimate is 7.59.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NV4P.MU. It's not an investment recommendation.
Tesla
10
TSLA
Apple
8
AAPL
Amazon
8
AMZN
NVIDIA
7
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap164.08M
ADC Therapeutics focuses on developing antibody-drug conjugates for cancer treatment, directly competing with Cellectar's cancer-targeting therapies.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in the broader cancer treatment landscape against Cellectar's offerings.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space, particularly in cell therapies that could be alternatives to Cellectar's treatments.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a broad range of oncology treatments, including targeted therapies and cell therapy products that compete with Cellectar's cancer treatments.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's extensive portfolio in oncology, including biosimilars and novel therapeutics, positions it as a competitor across various aspects of cancer treatment, challenging Cellectar's market.

About

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Show more...
CEO
Mr. James V. Caruso
Employees
11
Country
United States
ISIN
US15117F5008

Listings

F
DE
NV40.F
STU
DE
NV40.STU
MU
DE
NV4P.MU
MU
DE
NV40.MU

0 Comments

Share your thoughts

FAQ

What is Cellectar Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Cellectar Biosciences stocks are traded under the ticker NV4P.MU.
When is the next Cellectar Biosciences earnings date?▼
Cellectar Biosciences is going to release the next earnings report on August 19, 2026.
What were Cellectar Biosciences earnings last quarter?▼
NV4P.MU earnings for the last quarter are -1.14 EUR per share, whereas the estimation was -1.62 EUR resulting in a +29.44% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cellectar Biosciences revenue for the last year?▼
Cellectar Biosciences revenue for the last year amounts to 0 EUR.
What is Cellectar Biosciences net income for the last year?▼
NV4P.MU net income for the last year is -19.03M EUR.
How many employees does Cellectar Biosciences have?▼
As of July 27, 2026, the company has 11 employees.
In which sector is Cellectar Biosciences located?▼
Cellectar Biosciences operates in the Health & Wellness sector.
When did Cellectar Biosciences complete a stock split?▼
The last stock split for Cellectar Biosciences was on July 22, 2022 with a ratio of 1:10.
Where is Cellectar Biosciences headquartered?▼
Cellectar Biosciences is headquartered in Florham Park, United States.